Table 1.
All patients N (%) | Cavity shave margins N (%) | Standard PM N (%) | P value | |
---|---|---|---|---|
Patient demographics | ||||
Race | ||||
White | 251 (48.1) | 27 (40.3) | 224 (49.2) | 0.1913 |
Other | 271 (51.9) | 40 (59.7) | 231 (50.8) | |
Age at diagnosis | 57 | 58 | 57 | 0.5835 |
BMI | 29 kg/m2 | 30 kg/m2 | 29 kg/m2 | 0.107 |
Method tumor detected | ||||
MMG/ultrasound, Combination, other | 350 (67.0) | 48 (71.6) | 302 (66.4) | 0.4865 |
BSE, PE | 172 (33.0) | 19 (28.4) | 153 (33.6) | |
Tumor characteristics | ||||
Histology | ||||
IDC | 316 (60.5) | 39 (58.2) | 277 (60.9) | 0.6896 |
Other | 206 (39.5) | 28 (41.8) | 178 (39.1) | |
Associated LVI | ||||
Yes | 52 (13.5) | 5 (10.2) | 47 (13.9) | 0.6541 |
No | 334 (86.5) | 44 (89.8) | 290 (86.1) | |
ER status | ||||
Positive | 394 (76.4) | 53 (79.1) | 341 (75.9) | 0.6456 |
Negative | 122 (23.6) | 14 (20.9) | 108 (24.1) | |
Her 2 neu status | ||||
Positive | 89 (17.8) | 10 (15.4) | 79 (18.1) | 0.7282 |
Negative | 412 (82.2) | 55 (84.6) | 357 (81.9) | |
DCIS in final specimen | ||||
Yes | 384 (73.6) | 47 (70.1) | 337 (74.1) | 0.5529 |
No | 138 (26.4) | 20 (29.9) | 118 (25.9) | |
% DCIS | ||||
<25% | 177 (46.1) | 20 (42.6) | 157 (46.6) | 0.6419 |
>25% | 207 (53.9) | 27 (57.4) | 180 (53.4) | |
Therapy type | ||||
Neoadjuvant chemo/hormonal Therapy | ||||
Yes | 57 (10.9) | 9 (13.4) | 48 (10.5) | 0.5276 |
No | 465 (89.1) | 58 (86.6) | 407 (89.5) | |
Adjuvant chemo/hormonal Therapy | ||||
Yes | 205 (39.3) | 29 (43.3) | 176 (38.7) | 0.504 |
No | 317 (60.7) | 38 (56.7) | 279 (61.3) | |
Surgical localization | ||||
Breast surgery localization | ||||
Wire | 366 (70.8) | 44 (66.7) | 322 (71.4) | 0.469 |
No localization | 151 (29.2) | 22 (33.3) | 129 (28.6) |
PM: partial mastectomy; BMI: body mass index; MMG: mammogram; BSE: breast self exam; PE: physician exam; IDC: invasive ductal carcinoma; LVI: lymphovascular invasion; ER: estrogen receptor; Her 2 neu: human epidermal growth factor 2; DCIS: ductal carcinoma insitu; Chemo: chemotherapy.